Your browser doesn't support javascript.
loading
Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon ß Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan, Srividya; Oemar, Barry; Johnson, Kristen; Rath, Natalie; Salganik, Mikhail; Berman, Gabe; Pelletier, Kathleen; Cox, Lori; Page, Karen; Messing, Dean; Tarabar, Sanela.
Afiliación
  • Neelakantan S; Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Oemar B; Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Johnson K; Center for Therapeutic Innovation, Pfizer Inc, New York, New York, USA.
  • Rath N; Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Salganik M; Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Berman G; Pfizer Inc, San Diego, California, USA.
  • Pelletier K; Pfizer Inc, Groton, Connecticut, USA.
  • Cox L; Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Page K; Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Messing D; Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Tarabar S; Pfizer Clinical Research Unit, New Haven, Connecticut, USA.
Clin Pharmacol Drug Dev ; 10(3): 307-316, 2021 03.
Article en En | MEDLINE | ID: mdl-33352008
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Interferón beta / Inmunidad / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Interferón beta / Inmunidad / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2021 Tipo del documento: Article